Typhoid Conjugate Vaccines: Advancing the Research and Public Health Agendas.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
20 12 2021
Historique:
pubmed: 17 9 2021
medline: 27 1 2022
entrez: 16 9 2021
Statut: ppublish

Résumé

The disease burden of typhoid fever remains high in endemic areas in Asia and Africa, especially in children. Recent clinical trials conducted by the Typhoid Vaccine Acceleration Consortium show typhoid conjugate vaccine (TCV) to be safe, immunogenic, and efficacious at preventing blood culture-confirmed typhoid fever in African and Asian children. Pakistan, Liberia, and Zimbabwe recently introduced TCV through campaigns and routine childhood immunizations, providing protection for this vulnerable population. It is essential to continue this momentum while simultaneously filling data gaps-including typhoid complications-to inform decision-making on TCV introduction. A multidisciplinary approach including surveillance, water, sanitation, and hygiene investments, and large-scale TCV introduction is needed to decrease the burden and mortality of typhoid fever.

Identifiants

pubmed: 34528085
pii: 6370981
doi: 10.1093/infdis/jiab449
pmc: PMC8687070
doi:

Substances chimiques

Typhoid-Paratyphoid Vaccines 0
Vaccines, Conjugate 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

S781-S787

Subventions

Organisme : NIDDK NIH HHS
ID : T32 DK067872
Pays : United States

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.

Références

Lancet. 2021 Aug 21;398(10301):675-684
pubmed: 34384540
Clin Infect Dis. 2019 Mar 7;68(Suppl 2):S67-S73
pubmed: 30845329
Lancet Glob Health. 2021 Aug;9(8):e1154-e1162
pubmed: 34297962
Int J Infect Dis. 2021 Jan;102:517-523
pubmed: 33176205
J Infect Dis. 2021 Dec 20;224(Supplement_7):S770-S774
pubmed: 34374785
PLoS Negl Trop Dis. 2018 Oct 11;12(10):e0006779
pubmed: 30307935
Lancet. 2017 Dec 2;390(10111):2472-2480
pubmed: 28965718
PLoS Negl Trop Dis. 2020 Mar 18;14(3):e0008048
pubmed: 32187188
Clin Infect Dis. 2020 Jul 29;71(Suppl 2):S120-S126
pubmed: 32725232
J Infect. 2020 Dec;81(6):902-910
pubmed: 33144193
World J Surg. 2020 Sep;44(9):2892-2902
pubmed: 32430740
N Engl J Med. 2021 Sep 16;385(12):1104-1115
pubmed: 34525285
Clin Infect Dis. 2019 Feb 15;68(Suppl 1):S22-S26
pubmed: 30767002
Clin Infect Dis. 2019 Mar 7;68(Suppl 2):S50-S58
pubmed: 30845320
Clin Infect Dis. 2020 Jul 29;71(Suppl 2):S96-S101
pubmed: 32725231
Clin Infect Dis. 2015 Aug 1;61(3):393-402
pubmed: 25870324
N Engl J Med. 2019 Dec 5;381(23):2209-2218
pubmed: 31800986
Lancet Infect Dis. 2019 Sep;19(9):930
pubmed: 31478515
BMJ Open. 2017 Jul 2;7(6):e016283
pubmed: 28674145
Vaccine. 2017 Sep 12;35(38):5081-5088
pubmed: 28802757
J Infect Dis. 2018 Nov 10;218(suppl_4):S188-S194
pubmed: 30304505
Clin Infect Dis. 2016 Mar 15;62 Suppl 1:S1-3
pubmed: 26933014
Bull World Health Organ. 2004 May;82(5):346-53
pubmed: 15298225
Clin Infect Dis. 2019 Mar 7;68(Suppl 2):S59-S66
pubmed: 30845330
Clin Infect Dis. 2019 Mar 7;68(Suppl 2):S74-S82
pubmed: 30845333
Int J Infect Dis. 2021 Jul;108:465-472
pubmed: 34082090
Vaccine. 2019 Jan 7;37(2):214-216
pubmed: 29661581

Auteurs

Megan Birkhold (M)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Aziza Mwisongo (A)

Center for Vaccine Innovation and Access, PATH , Seattle, Washington, USA.

Andrew J Pollard (AJ)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
National Institute for Health Research Oxford Biomedical Research Centre, Oxford, United Kingdom.

Kathleen M Neuzil (KM)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH